Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy

NCT00057811 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00057811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
July 31, 2014
Enrollment
97 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, stage i childhood large cell lymphoma, stage i childhood small noncleaved cell lymphoma, stage ii childhood large cell lymphoma, stage ii childhood small noncleaved cell lymphoma, stage iii childhood large cell lymphoma, stage iii childhood small noncleaved cell lymphoma, stage iv childhood large cell lymphoma, stage iv childhood small noncleaved cell lymphoma, untreated childhood acute lymphoblastic leukemia